Stage IV Breast Cancer: Nathalie's Patient Story

Patient Info: Nathalie | Stage IV

Nathalie had been living with stage 4 breast cancer for more than three years and remained focused on time with her children.

Our Cancer StoriesRead more →

Triple-Negative Invasive Ductal Carcinoma: Katherine's Patient Story

Patient Info: Katherine Humphrey, Female, Under 40

Biomarkers: triple-negative

Recovering after bilateral mastectomy and additional chemotherapy, with capecitabine planned for fall 2026.

Dana-FarberRead more →

Stage IV HER2-Positive Breast Cancer: Jennifer's Patient Story

Patient Info: Jennifer Feinberg, Female, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: brain

8+ years after her initial breast cancer diagnosis, she was living with metastatic HER2-positive breast cancer with brain metastases and receiving trastuzumab as her tenth line of treatment.

Dana-FarberRead more →

HER2-positive breast cancer complicated by severe anemia during chemotherapy

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-positive; germline BRCA1 likely pathogenic mutation

At 4.5-year follow-up, she remained free of breast-cancer recurrence and had no recurrence of the severe treatment-related anemia.

PubMed CentralRead more →

Stage II Breast Cancer: Renée's Survivor Story

Patient Info: Renée, Female, Under 40 | Stage II

Renée described her health as stable and her treatment as working. She remained on a long-term hormone-based anti-cancer regimen and was still healing from reconstruction complications rather than describing herself as cancer-free.

The Patient StoryRead more →

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient StoryRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Shari's Patient Story

Patient Info: Shari S., Female | Stage IV

Biomarkers: ER-positive, PR-positive and HER2-positive; no inherited cancer mutation was identified

Metastatic Site: Brain; other initial metastatic sites were not named

Systemic imaging after chemotherapy showed no active disease, but brain metastases later required stereotactic radiation. Shari remained stage 4, continued Herceptin every 3 weeks and underwent brain MRI every 3–4 months.

The Patient StoryRead more →

Stage IV Triple-Negative Breast Cancer: Janice's Patient Story

Patient Info: Janice, Female, Under 40 | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: Other sites not specified

Living with incurable Stage IV triple-negative breast cancer while advocating for dose adjustments, symptom management, and balancing quality of life with survival.

The Patient StoryRead more →

Stage III HER2-Positive Breast Cancer: Genoa's Survivor Story

Patient Info: Genoa M., Female | Stage III

Biomarkers: HER2-positive; ER-positive

As of June 2026, Genoa had completed treatment for Stage III HER2-positive, ER-positive breast cancer with neoadjuvant Taxotere/carboplatin/trastuzumab, lumpectomy, and radiation, and was focused on survivorship and rebuilding life after treatment.

The Patient StoryRead more →

Stage I HR-Positive Invasive Ductal Carcinoma: Amelia's Patient Story

Patient Info: Amelia, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; BRCA negative; Oncotype DX score 22

As of June 2026, Amelia had no evidence of disease after lumpectomy, bilateral mastectomy, TC chemotherapy, and reconstruction, and she remained on tamoxifen.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Doreen's Patient Story

Patient Info: Doreen, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Doreen had completed TCHP chemotherapy with a complete response before surgery and had undergone lumpectomy and radiation for Stage IIA triple-positive breast cancer.

The Patient StoryRead more →

Metastatic triple-negative breast cancer with orbital and bone metastases responding to nab-paclitaxel plus everolimus

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary breast cancer was ER-low, PR/HER2 negative. Orbital metastasis was triple-negative with AKT1 exon 4 mutation.

Metastatic Site: right orbit/orbital mass; bone

At 6-month follow-up, systemic disease was stable, ocular symptoms had significantly improved, orbital metastases were stable on MRI, and the response was described as RECIST partial response/progression-free interval while treatment continued.

PubMed CentralRead more →

Breast cancer treatment during pregnancy followed by postpartum targeted therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

She achieved a near-complete response after 4 cycles of docetaxel and then continued systemic treatment after delivery.

PubMed CentralRead more →

Stage IV Breast Cancer: Gynna's Patient Story

Patient Info: Gynna, Female, Under 40 | Stage IV

Metastatic Site: Bone

As of May 2026, Gynna was living with Stage IV metastatic breast cancer in the bones; after progression in June 2025, she had a partial response by December 2025 and continued indefinite treatment.

Stage I luminal A invasive ductal breast cancer with post-treatment cognitive symptoms

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: ER 100% positive; PR 95% positive; HER2 score 0 / HER2-negative; Ki-67 10%; P63 negative

As of April 2026, the case focused on survivorship after Stage I luminal A breast cancer treatment, with cognitive complaints after chemotherapy and improved MoCA and depression scores after 12 sessions of tDCS; brain metastases had been ruled out.

PubMed CentralRead more →

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed CentralRead more →

Stage 4 breast cancer: 4 years and counting

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor: hormone receptor-positive; HER2 1+. Metastatic recurrence: triple-negative breast cancer.

Metastatic Site: liver, bone, lung, supraclavicular lymph nodes,…

After response of choroidal metastases to eye radiation plus sacituzumab govitecan, disease progressed in February 2023 with cerebellar and pituitary brain lesions; she developed obstructive hydrocephalus, entered hospice in May 2023, and died in June 2023.

PubMed CentralRead more →

Synchronous EGFR-mutated lung adenocarcinoma and metastatic breast cancer: surgery and adjuvant therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Two cancers: lung adenocarcinoma with EGFR exon 19 deletion; breast cancer ER-positive, PR-low, HER2 non-amplified.

Metastatic Site: lung

Follow-up CT on 26 December 2024 showed no recurrence, with disease-free survival estimated at 27 months to 1 April 2025 while on icotinib and letrozole maintenance.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Paul's Patient Story

Patient Info: Paul Forgette, Male, 60s | Stage IV

Biomarkers: HER2-positive; triple-positive breast cancer; CHEK2 mutation

Metastatic Site: Bones; lymph nodes

By October 2025, 9 months after starting Enhertu, Paul’s Stage IV HER2-positive male breast cancer was described as dormant, not cured, with continued City of Hope care and integrative support.

City of HopeRead more →

Invasive lobular breast cancer with dense lymphocytic infiltration treated with surgery, radiation, chemotherapy, and endocrine therapy

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-positive/PR-negative, HER2 1+ lobular breast cancer; Ki-67 35%

At 1 year after surgery, the patient remained recurrence-free while receiving postmenopausal aromatase inhibitor endocrine therapy.

PubMed CentralRead more →

HER2-positive Stage IV breast cancer: T-DM1 extravasation wound healed after multidisciplinary care

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 70% positive; HER2 IHC 3+

Metastatic Site: pelvis

As of October 2025, the T-DM1 extravasation wound had almost fully healed within about 4 weeks, and the patient continued adjuvant T-DM1 through a port; longer cancer-control status was not described.

PubMed CentralRead more →

Stage IIIA triple-negative breast cancer with hypercalcemia from parathyroid adenoma

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

As of October 2025, evaluation for post-chemotherapy weakness showed no local breast cancer recurrence, no lymphadenopathy, and no bone metastases; hypercalcemia resolved after parathyroid adenoma removal while breast cancer care remained ongoing.

PubMed CentralRead more →

Stage IIA breast collision tumor: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Two breast tumor parts were ER-positive; one HER2-low/negative and one HER2-positive. BRCA testing was suggested but not done.

Four years after surgery, she remained disease-free after mastectomy, adjuvant chemotherapy, HER2-targeted therapy, and endocrine therapy.

PubMed CentralRead more →

HER2-positive invasive lobular breast cancer in a transgender man: disease-free after multimodality care

Patient Info: Anonymized, transgender man, 70+ | Stage III

Biomarkers: HER2-positive invasive lobular breast cancer, ER/PR negative

Nearly 2 years after diagnosis, he remained disease-free while continuing survivorship care and counseling after discontinuing testosterone therapy.

PubMed CentralRead more →